UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.79−0.08 (-0.27%)
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma total assets
Total assets on the balance sheet at the end of each period.
UroGen Pharma's total assets was $252.59M at Jun 30, 2026. For fiscal 2025 it was $200.46M, down 29.8% from the year before. The highest annual figure on record is $285.71M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $200.46M | -29.8% |
| FY2024 | Dec 31, 2024 | $285.71M | +60.2% |
| FY2023 | Dec 31, 2023 | $178.31M | +31.5% |
| FY2022 | Dec 31, 2022 | $135.62M | +13.3% |
| FY2021 | Dec 31, 2021 | $119.75M | -1.9% |
| FY2020 | Dec 31, 2020 | $122.01M | -39.7% |
| FY2019 | Dec 31, 2019 | $202.39M | +95.4% |
| FY2018 | Dec 31, 2018 | $103.56M | +37.1% |
| FY2017 | Dec 31, 2017 | $75.55M | +227.7% |
| FY2016 | Dec 31, 2016 | $23.06M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $252.59M | +21.0% |
| Q1 FY2026 | Mar 31, 2026 | $253.69M | +2.5% |
| Q4 FY2025 | Dec 31, 2025 | $200.46M | -29.8% |
| Q3 FY2025 | Sep 30, 2025 | $185.05M | -38.7% |
| Q2 FY2025 | Jun 30, 2025 | $208.72M | -25.9% |
| Q1 FY2025 | Mar 31, 2025 | $247.62M | +23.5% |
| Q4 FY2024 | Dec 31, 2024 | $285.71M | +60.2% |
| Q3 FY2024 | Sep 30, 2024 | $301.94M | +55.9% |
| Q2 FY2024 | Jun 30, 2024 | $281.85M | +195.6% |
| Q1 FY2024 | Mar 31, 2024 | $200.57M | +77.6% |
| Q4 FY2023 | Dec 31, 2023 | $178.31M | +31.5% |
| Q3 FY2023 | Sep 30, 2023 | $193.63M | +50.7% |
| Q2 FY2023 | Jun 30, 2023 | $95.36M | -34.7% |
| Q1 FY2023 | Mar 31, 2023 | $112.95M | -31.8% |
| Q4 FY2022 | Dec 31, 2022 | $135.62M | +13.3% |
| Q3 FY2022 | Sep 30, 2022 | $128.47M | -4.6% |
| Q2 FY2022 | Jun 30, 2022 | $146.14M | -5.0% |
| Q1 FY2022 | Mar 31, 2022 | $165.72M | +70.1% |
| Q4 FY2021 | Dec 31, 2021 | $119.75M | -1.9% |
| Q3 FY2021 | Sep 30, 2021 | $134.60M | -3.8% |
| Q2 FY2021 | Jun 30, 2021 | $153.77M | -4.5% |
| Q1 FY2021 | Mar 31, 2021 | $97.41M | -41.6% |
| Q4 FY2020 | Dec 31, 2020 | $122.01M | -39.7% |
| Q3 FY2020 | Sep 30, 2020 | $139.89M | -38.3% |
| Q2 FY2020 | Jun 30, 2020 | $161.08M | -32.5% |
| Q1 FY2020 | Mar 31, 2020 | $166.93M | -33.8% |
| Q4 FY2019 | Dec 31, 2019 | $202.39M | +95.4% |
| Q3 FY2019 | Sep 30, 2019 | $226.75M | +101.5% |
| Q2 FY2019 | Jun 30, 2019 | $238.57M | +96.3% |
| Q1 FY2019 | Mar 31, 2019 | $252.05M | +94.8% |
| Q4 FY2018 | Dec 31, 2018 | $103.56M | +37.1% |
| Q3 FY2018 | Sep 30, 2018 | $112.56M | +388.2% |
| Q2 FY2018 | Jun 30, 2018 | $121.50M | – |
| Q1 FY2018 | Mar 31, 2018 | $129.40M | – |
| Q4 FY2017 | Dec 31, 2017 | $75.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $23.06M | – |
See a number that looks wrong?